BioCentury
ARTICLE | Clinical News

ZPL-389: Phase IIa data

May 23, 2016 7:00 AM UTC

Top-line data from a double-blind, European Phase IIa trial in 98 patients with moderate to severe atopic dermatitis showed that once-daily 30 mg oral ZPL-389 missed the primary endpoint of improving ...